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Abstract
Risk factors for hypertension consist of lifestyle and genetic factors. Family history and twin studies have yielded
heritability estimates of BP in the range of 34–67%. The most recent paper of BP GWAS has explained about 20% of
the population variation of BP. An overestimation of heritability may have occurred in twin studies due to violations
of shared environment assumptions, poor phenotyping practices in control cohorts, failure to account for epistasis,
gene-gene and gene-environment interactions, and other non-genetic sources of phenotype modulation that are
suspected to lead to underestimations of heritability in GWAS. The recommendations of hypertension guidelines in
major countries consist of the following elements: weight reduction, a healthy diet, dietary sodium reduction,
increasing physical activity, quitting smoking, and moderate alcohol consumption. The hypertension guidelines are
mostly the same for each country or region, beyond race and culture. In this review, we summarize gene-
environmental interactions associated with hypertension by describing lifestyle modifications according to the
hypertension guidelines. In the era of precision medicine, clinicians who are responsible for hypertension
management should consider the gene-environment interactions along with the appropriate lifestyle components
toward the prevention and treatment of hypertension. We briefly reviewed the interaction of genetic and
environmental factors along the constituent elements of hypertension guidelines, but a sufficient amount of
evidence has not yet accumulated, and the results of genetic factors often differed in each study.
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Hypertension is the most influential risk factor for car-
diovascular disease (CVD) [1]. Recent evidence has sug-
gested that hypertension is also associated with common
non-CVD such as dementia and renal dysfunction [2].
Risk factors for hypertension consist of lifestyle and gen-
etic factors. Family history and twin studies have yielded
heritability estimates of blood pressure (BP) in the range
of 34–67% [3]. The collective effect of all BP loci identi-
fied through genome-wide association studies (GWAS)
accounted for only ~ 3.5% of BP variability [4]. The most
recent paper of BP GWAS has identified 901 SNPs with
BP and explained about 20% of the population variation
of BP [5]. An overestimation of heritability may have
occurred in twin studies due to violations of shared
environment assumptions, poor phenotyping practices
in control cohorts, failure to account for epistasis,
gene-gene (G × G) and gene-environment (G × E)
interactions, and other non-genetic sources of phenotype
modulation that are suspected to lead to underestima-
tions of heritability in GWAS.
The recommendations of hypertension guidelines in
major countries consist of the following elements:
weight reduction, a healthy diet (dietary patterns charac-
terized by a high consumption of fruit, vegetables, whole
grains, legumes, seeds, nuts, fish, low-fat dairy, and a
low consumption of meat and sweets), dietary sodium
reduction, increasing physical activity, quitting smoking
(including avoiding passive smoking), and moderate
alcohol consumption (Table 1) [6–8]. The hypertension
guidelines are mostly the same for each country or
region, beyond race and culture [9]. In this review, we
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summarize gene-environmental interactions associated
with hypertension by describing lifestyle modifications
according to the hypertension guidelines.
Gene-sodium interaction
The INTERSALT study indicated an association between
overdose salt intake and high blood pressure [10]. The
Dietary Approaches to Stop Hypertension (DASH) study
showed that sodium intake restrictions from a high level
to an intermediate level and from an intermediate to a low
level reduced both systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) [11]. In a pooled analysis of
data, lowering sodium intake was shown to be
best-targeted at individuals with hypertension who con-
sume high-sodium diets [12]. On the basis of these results,
hypertension management guidelines recommend the fol-
lowing: salt intakes of < 5 g/day in Europe [6], < 6 g/day in
Japan [8], and sodium intake of < 1500 mg/day (salt intake
of < 3. 81 g/day equivalent) in the USA [7].
Salt sensitivity is an increase in BP in response to
excessive dietary salt intake, and it is associated with
genetic and environmental factors. Salt sensitivity is
more frequently observed in hypertensive than normo-
tensive subjects, in colored races than in Caucasians,
and in older than in younger subjects [13, 14]. When
gene-sodium interactions are studied, the investigations
must consider the race and age group of subjects.
A cross-sectional study in Korea indicated that the
mutant alleles of CSK rs1378942 and CSK-MIR4513
rs3784789 had the strongest protective effects against
hypertension in the subjects in the middle group of the
24-h estimated urinary sodium-potassium excretion ratio
(Table 2) [15]. In a cross-sectional study in China, Li et al.
showed that the interaction for CLGN rs2567241 was
associated with the sodium intake’s effects on SBP, DBP,
and mean blood pressure (MBP), the impact of UST
rs13211840 on DBP, and the effect of LOC105369882
rs11104632 on SBP through the examination of an SNP
[16]. Also, genome-wide gene-based interactions with so-
dium identified MKNK1, C2orf80, EPHA6, SCOC-AS1,
SCOC, CLGN, MGAT4D, ARHGAP42, CASP4, and
LINC01478 which were associated with at least one BP
variable. In Chinese Kazakh women, an interaction of
ACE genotype and salt intake on hypertension was
observed [17].
In a Japanese population, the interaction between salt
consumption and NPPA rs5063 (Val32Met) showed a
significant association with SBP [18]. In a general
Table 1 Comparison between three major lifestyle modifications in the hypertension guidelines
ESH/ESC Guideline 2018 [6] ACC/AHA Guideline 2017 [7] JSH Guideline 2014 [8]
Dietary sodium
restriction
Salt restriction to < 5 g/day Optimal goal is < 1500 mg/day, but aim
for at least a 1000 mg/day reduction in
most adults.
The target of salt reduction is < 6 g/day.
Other dietary
changes
Increased consumption of vegetables,
fresh fruits, fish, nuts, and unsaturated
fatty acids (olive oil); low consumption
of red meat; and consumption of
low-fat dairy products
A heart-healthy diet, such as the DASH
diet, that facilitates achieving a desirable
weight is recommended for adults with
elevated BP or hypertension.
Potassium supplementation, preferably in
dietary modification, is recommended
for adults with elevated BP or hypertension,
unless contraindicated by the presence of
CKD or use of drugs that reduce
potassium excretion.
Dietary pattern: fruit/vegetable intake
should be increased, and cholesterol/
saturated fatty acid intake should be
reduced. Fish (fish oil) intake should
also be increased.
Weight
reduction
Body-weight control is indicated
to avoid obesity (BMI > 30 kg/m2 or waist
circumference > 102 cm [men] and
> 88 cm [women], as is aiming at healthy
BMI (about 20–25 kg/m2) and waist
circumference (< 94 cm [men] and
< 80 cm [women])
Weight loss is recommended to reduce
BP in adults with elevated BP or
hypertension who are overweight
or obese.
The target body mass index is
< 25 kg/m2. Even when the target is not
reached, a significant decrease in blood
pressure can be achieved by reducing
body weight by approximately 4 kg.
Regular physical
activity
Regular aerobic exercise (e.g., at least
30 min of moderate dynamic exercise
on 5–7 days/week)
Increased physical activity with a
structured exercise program is
recommended for adults with
elevated BP or hypertension.
Primarily periodic (30 min or longer
daily if possible) and aerobic
exercise should be practiced.
Smoking
cessation
Smoking cessation, supportive care,
and referral to smoking
cessation programs
Quit cigarette smoking and
second-hand smoking.
Smoking cessation should be promoted,
and passive smoking must be avoided.
Moderate alcohol
consumption
Men: < 14 units/week
Women: < 8 units/week
Avoid binge drinking
Adult men and women with elevated BP
or hypertension who currently consume
alcohol should be advised to drink no
more than 28 g/day and 24 g/day as
ethanol, respectively.
Alcohol intake should be restricted.
≤ 20–30 mL/day in men and
≤ 10–20 mL/day in women as ethanol.
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Japanese population, a high sodium intake strengthened
the association of AGT T174M [19] and ADD1 G460W
(only women) [20] polymorphisms with hypertension
and SBP levels, respectively. Another cross-sectional
study showed that CYP3A5 variants might be a deter-
minant of salt sensitivity of BP in Japanese men [21]. A
case-control study in Taiwan showed that GNB3 C825T
polymorphism might increase the risk of hypertension
among individuals who consumed a high-sodium diet
[22]. Adamo et al. reviewed studies of gene-salt
interaction [23], but most of those studies might have
been subject to error due to their small sample sizes.
Studies of gene-environmental interactions require large
sample sizes as they involve the grouping of genes and
environmental factors.
Gene-healthy diet interaction
The DASH diet study showed no significant BP lowering
in the control group, and the fruits/vegetable group, but
SBP and DBP lowering were observed in the DASH diet
group [24]. In a meta-analysis of 17 randomized
controlled trials, significant reductions of 4.3 mmHg in
SBP and 2.4 mmHg in DBP were observed in healthy
dietary patterns, including the DASH diet, Nordic diet,
and Mediterranean diet, all of which include the high
consumption of fruit, vegetables, whole grains, legumes,
seeds, nuts, fish, and dairy and a low consumption of
meat, sweets, and alcohol [25]. These foods or combin-
ational foods contribute to the prevention of high blood
pressure.
A 2-year-randomized intervention trial revealed
significant interactions between the Neuropeptide Y
(NPY) rs16147 SNP and dietary fat intake in relation to
changes in SBP and DBP (Table 3) [26]. The gene-diet
interactions appeared only in hypertensive patients.
During the 2 years of intervention, the subjects with C
allele had greater reductions in SBP and DBP in
response to a low-fat diet but had greater increases in
SBP and DBP in response to a high-fat diet. NPY is
implicated in the regulation of BP, and NPY pathways in
the hypothalamus are sensitive to dietary fat. Animal
experiments indicated that fat intake and NPY activity in
the hypothalamus are inversely correlated [27].
A Korean genome and epidemiology study showed
that a higher omega-3 (ω-3) polyunsaturated fatty acid
(PUFA) intake was significantly associated with a more
Table 2 Review for interaction of gene and salt intake on hypertension
Population Gene SNPs/gene length, bp Chr Position Trait Reference
Korea LOC101929750 rs7554672 1 219339781 HT 24hUNa, K 15
MKLN1 rs1643270 7 130826034 HT 24hUK
CSK rs1378942 15 72864420 HT 24hUNa/K
CSK-MIR4513 rs3784789 15 72869605 HT
TENM4 rs10466739 11 78290369 HT
Taiwan GNB3 rs5443 10 HT Salt intake 22
China CLGN rs2567241 4 141542612 SBP, DBP, MBP Salt intake 16
LOC105 rs11104632 12 86747816 SBP
UST rs13211840 6 149153883 DBP
China MKNK1 46889 1 46795665 SBP Salt intake 17
SCOC 39097 4 141484064 SBP, DBP, MBP
SCOC-AS1 89668 4 141424329 DBP, MBP
CLGN 39210 4 141529056 SBP, DBP, MBP
MGAT4D 55004 4 141583978 SBP, DBP, MBP
LINC01478 208264 18 40157397 SBP
C2orf80 24704 2 208738315 PP
EPHA6 429464 3 98641126 PP
ARHGAP42 303251 11 100063616 PP
Japan NPPA rs5063 1 11907648 SBP Salt intake 18
Japan CYP3A5 rs776746 3 SBP, DBP 24hUNaCl 21
Japan AGT T174 M HT 24hUNa, sodium intake 19
Japan ADD1 G460W SBP 24hUNa, sodium intake 20
HT hypertension, SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure, PP pulse pressure, 24hUNa 24-h sodium excretion; 24-h
potassium excretion; 24-h salt excretion
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pronounced BP decrease over time in subjects with the
CYP4F2 433VV genotype, although there was no associ-
ation between ω-6 and ω-3 PUFA intakes, ω-6/ω-3, and
changes of BP [28]. A meta-analysis of interventional
studies showed that the intake of fish oil caused a
decrease in BP in hypertensive patients [29].
In a study of Japanese men, the Met allele of COMT
Val158Met was associated with higher BP and a higher
prevalence of hypertension in the high-energy intake
group but not in the low-energy intake group [30].
There was no difference in body mass index (BMI)
between the low- and high-energy intake groups. The
underlying mechanism of these results remains unclear.
In a Southern European study, there was an inter-
action between the NOS3 rs1799983 polymorphism and
dietary saturated fatty acid and monounsaturated fatty
acid that influenced DBP levels [31]. Martins et al.
showed that nitric oxide synthase (NOS) activity was
increased in an unsaturated high-fat diet group. The
expressions of endothelial NOS (eNOS) and inducible
NOS (iNOS) were also increased in the unsaturated
high-fat diets group [32]. These changes may be involved
in gene-dietary interactions.
Gene-alcohol interaction
Alcohol consumption is higher among East Asian men
compared to Western men, but the consumption of al-
cohol by Western women is higher than that among
East Asian women [33]. Approximately half of East
Asians are found to be aldehyde dehydrogenase (ALDH)
deficient, which accounts for a phenomenon called the
‘Oriental flushing syndrome.’ ALDH deficiency poses an
increased risk of high BP [34].
In a study of middle-aged Finnish men, the apolipo-
protein E phenotype significantly influenced the BP in-
creasing effect of alcohol consumption (Table 4) [35]. A
cross-sectional study of a Chinese population showed a
significant interaction between the CYP11B2 genotype
[36] and DNA methylation (CpG1 methylation) of the
ADD1 gene promoter [37] and alcohol consumption on
the risk of hypertension. In addition, the Stanford
Asia-Pacific Program for Hypertension and Insulin
Resistance (SAPPHIRe) study showed that ALDH2
genetic variants were associated with progression to
hypertension in a prospective Chinese cohort [38]. In a
cross-sectional study of 5724 Japanese participants,
ALDH2 rs671 significantly and synergistically influenced
the subjects’ drinking behavior and influenced the level
of BP independently of the amount of alcohol consump-
tion [39], but not in another study, in a case-control
study of 532 Japanese patients, there was no significant
interaction between the ALDH2 genotype and alcohol
consumption overall or in Japanese male patients: this
study may have had insufficient power to detect the
interaction [40].
A genome-wide analysis of the effect of SNP-alcohol
interactions on BP traits showed 1 significant and 20
suggestive BP loci by exploiting gene-alcohol interac-
tions in a study from the Framingham SNP Health Asso-
ciation Resource [41]. The CHARGE Gene-Lifestyle
Interactions Working Group has systematically shown
the gene-alcohol interaction on BP in a recent and
extensive meta-analysis across multiple ancestries, con-
ducting a large two-stage investigation incorporating
joint testing of main genetic effects and single nucleotide
variant (SNV)-alcohol consumption interactions [42].
The study identified and replicated 54 BP loci in
European ancestry and multi-ancestry meta-analyses.
Gene-smoking interaction
According to the Global Burden of Disease Study 2015,
central and eastern Europe and southeast Asia had a
higher prevalence of smoking than the global average for
men, and western and central Europe had a higher
prevalence of smoking than the global average for
women [43]. The population-attributable fractions of
coronary heart disease caused by smoking among men
and women were higher in the East Asian region than in
the Western Pacific region [44].
In a rural Chinese population, the cigarette smoking
index and ACE gene showed a low exposure-gene ef-
fect on essential hypertension with interaction indices
(Table 5) [45]. In an eastern Chinese Han population,
gene-environment interactions between rs1126742 and
smoking were associated with an increased risk of essential
hypertension [46]. A case-control study showed the associ-
ation of KCNJ11 gene polymorphisms and BP response to
the antihypertensive drug irbesartan in non-smoking
Table 3 Review for interaction of gene and healthy diet on hypertension
National gene SNPs/gene length, bp Chr Results Healthy diet Reference
USA NPY rs16147 SBP, DBP Dietary fat intake 26
Korea CYP4F2 433VV BP change ω-3 PUFA 28
Japan COMT Val158Met 22 higher BP and HT High-energy intake 30
Spain NOS3 rs1799983 DBP Monounsaturated fatty acid 31
Saturated fatty acid
See Table 2 footnote
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Table 4 Review for interaction of gene and alcohol intake on hypertension
Population Gene SNPs/gene length, bp Chr Position Results Drink Ancestor Reference
Finland APOE SBP LHD 35
China ADD1 rs4961 4 HT alcohol/w 37
China CYP11B2 HT alcohol/w 36
China ALDH2 rs2238152 12 111776655 HT LHD 38
Japan ALDH2 rs671 12 HT alcohol/w 39
USA MGC27382-PTGFR rs648425 1 78659796 SBP Drinks/w 41
ESRRG rs17669622 1 214823444 MAP Drinks/w
RAB4A rs16849553 1 227403469 MAP Oz alcohol/w
FAM179A rs13008299 2 29101501 DBP Drinks/w
CRIPT-SOCS5 rs4953404 2 46739646 PP Days drinks/w, Oz alcohol/w
KAT2B rs9874923 3 20076567 MAP Drinks/w
Intergenic rs3852160 5 5875647 MAP Days drinks/w
ADCY2 rs4537030 5 7296981 MAP Drinks/w
GLI3 rs7791745 7 42351145 MAP Drinks/w
ZNF716 rs11766519 7 57587798 PP Days drinks/w
SLC16A9 rs10826334 10 61050488 SBP,MAP Oz alcohol/w
SLC16A9 rs10826334 10 61050488 SBP Drinks/w
SLIT1 rs12773465 10 98784049 MAP Drinks/w
SLIT1 rs7902871 10 98799693 DBP Drinks/w
Intergenic rs7116456 11 23911889 SBP Drinks/w
Intergenic rs12292796 11 39382675 PP Drinks/w
PDE3A rs10841530 12 20490379 SBP Drinks/w
KERA-LUM rs991427 12 89998553 SBP Oz alcohol/w
KERA-LUM rs4494364 12 90001245 SBP Drinks/w
RNF219-AS1 rs9318552 13 77923788 DBP Oz alcohol/w
CLEC3A rs2735413 16 76611144 SBP Drinks/w
WFDC1 rs16963349 16 82895735 SBP Drinks/w
FBXO15 rs1943940 18 69856172 DBP,MAP Drinks/w
IGSF5 rs2410182 21 40101946 SBP Oz alcohol/w
IGSF5-PCP4 rs2837253 21 40143126 SBP Drinks/w
Multiple BLK rs2409784 8 11539347 DBP CURD EA,HA 42
BLK rs6983727 8 11558303 SBP LHD EA
BLK rs6983727 8 11558303 PP CURD,LHD EA
BLK rs34190028 8 11559641 SBP CURD EA
CDH17 rs115888294 8 94105161 PP CURD AA
CORO2A rs73655199 9 98145201 PP CURD AA
ELMOD1 rs139077481 11 107579224 PP CURD AA
ERCC6 rs4253197 10 49473111 PP CURD AA
EYS rs80158983 6 65489746 SBP CURD AA
FAM167A rs12156009 8 11427710 SBP CURD EA
FAM167A rs13255193 8 11451683 SBP LHD EA
FAM167A-AS1 rs9969423 8 11398066 SBP CURD,LHD EA
FTO rs9928094 16 53765993 PP CURD ASA,EA
FTO rs55872725 16 53775211 SBP CURD EA
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Table 4 Review for interaction of gene and alcohol intake on hypertension (Continued)
Population Gene SNPs/gene length, bp Chr Position Results Drink Ancestor Reference
FTO rs7185735 16 53788739 PP CURD EA
FTO rs62033406 16 53790314 MAP CURD ASA,EA
GALNT18 rs10741534 11 11233360 SBP CURD AA
GATA4 rs3735814 8 11749887 SBP CURD EA,HA
GATA4 rs36038176 8 11752486 SBP CURD EA
LINC00208 rs899366 8 11572976 MAP CURD EA
LINC00208 rs7464263 8 11576667 SBP LHD EA
LINC00208 rs2244894 8 11591150 PP CURD ASA,EA
LINC00208 rs1478894 8 11591245 SBP CURD EA
LINC00208 rs4841569 8 11594668 PP CURD,LHD EA
LINC00208 rs13249843 8 11601509 DBP CURD EA,HA
LINC00208 rs17807624 8 11605506 DBP CURD EA
LINC00208 rs17807624 8 11605506 MAP LHD EA
LOC102723313 rs13276026 8 10752445 SBP CURD EA
LOC102723313 rs13276026 8 10752445 DBP,MAP CURD EA,HA
LOC102724880 rs453301 8 9172877 SBP CURD EA
LOC102724880 rs453301 8 9172877 DBP CURD EA,HA
LOC105372045 rs140520944 18 29508647 PP CURD AA
LOC105372361 rs142673685 19 31669942 PP CURD AA
LOC105379224 rs2980755 8 8506173 SBP,PP LHD EA
LOC105379224 rs10092965 8 8515975 DBP CURD EA,HA
LOC105379224 rs13270194 8 8520592 SBP CURD EA
LOC105379224 rs7823056 8 8525195 SBP,PP LHD AA,EA
LOC105379224 rs6995407 8 8527137 PP CURD EA
LOC105379231 rs6601302 8 9381948 SBP CURD EA
LOC105379235 rs9650622 8 9946782 DBP CURD EA
LOC105379235 rs56243511 8 9948185 SBP CURD EA
LOC105379235 rs656319 8 9956901 SBP,MAP LHD EA
LOC105379242 rs13280442 8 11610048 SBP,MAP CURD,LHD EA
LOC105379242 rs13250871 8 11610254 PP CURD,LHD EA
LOC107986913 rs2979172 8 8452998 PP LHD EA
LOC107986913 rs2921064 8 8459127 PP CURD EA
LOC107986913 rs2979181 8 8465578 SBP CURD,LHD EA
LOC157273 rs10503387 8 9293015 SBP CURD AA,EA
LOC157273 rs11781008 8 9295729 DBP CURD EA,HA
LOC157273 rs11774915 8 9331252 SBP CURD EA
MIR124–1 rs483916 8 9936091 SBP,DBP,PP CURD EA
MIR124–1 rs615632 8 9938811 SBP LHD EA
MIR4286 rs7814795 8 10661775 SBP CURD,LHD EA
MIR4286 rs7814795 8 10661775 MAP CURD EA
MIR4286 rs28680211 8 10661935 MAP LHD EA
MSRA rs2062331 8 10122482 DBP CURD EA
MSRA rs11993089 8 10152442 PP CURD EA
MSRA rs34919878 8 10241994 DBP CURD EA,HA
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Chinese hypertensive patients [47]. As a genome-wide
study, the Framingham Heart Study identified 7 significant
and 21 suggestive BP loci by gene-smoking interactions in
an analysis of 6889 participants [48].
The further genome-wide research was proposed to
examine African American participants in the Hyperten-
sion Genetic Epidemiology Network (HyperGEN)
research, and testing the association in African American
participants from the Genetic Epidemiology Network of
Arteriopathy (GENOA) study [49]. The results suggested
that NEDD8 rs11158609 and TTYH2 rs8078051 were
associated with SBP including the genetic interaction with
cigarette smoking, although these two SNPs were not
associated with SBP in a main genetic effect model.
Gene-obesity interaction
Globally, the prevalence of overweight or obesity for
adults increased from 28.8% and 29.8% in 1980 to 36.9%
and 38.0% in 2013 for men and women, respectively,
which were observed in both developed and developing
countries [50]. The prevalence of overweight and obesity
is rising among children and adolescents in developing
countries as well, rising from 8.1% and 8.4% in 1980 to
12.9% and 13.4% in 2013 for boys and girls, respectively.
A meta-analysis of 25 studies has estimated that as body
weight decreased by 1 kg, SBP and DBP decreased by −
1.05 mmHg and − 0.92 mmHg, respectively [51]. There-
fore, weight loss for obese people is an essential factor in
lowering BP.
The Atherosclerosis Risk in Communities Study showed
a significant interaction among the GNB3 C825T poly-
morphism, obesity status, and physical activity in predict-
ing hypertension in African American subjects, and those
who were both obese and had a low activity level with T
allele were 2.7 times more likely to be hypertensive com-
pared to non-obese, active C homozygotes [52].
The representative SNPs related to BMI are those in
FTO and MC4-R loci. SNPs in FTO were associated with
hypertension in different ethnic groups [53]. The Pima In-
dians in Arizona have the highest prevalence of obesity in
the world, but a relatively low prevalence of hypertension
and atherosclerotic disease [54]. The lack of increase in
muscle sympathetic nerve activity with increasing adipos-
ity and insulinemia in Pima Indians may explain this in
part [55], but the reason why this population has a low
tendency for hypertension despite the high prevalence of
obesity and hyperinsulinemia are not yet known.
Gene-physical activity interaction
A meta-analysis that included 13 prospective studies
suggested that there was an inverse dose-response asso-
ciation between levels of recreational physical activity
and risk of hypertension [56]. A recent systematic review
Table 4 Review for interaction of gene and alcohol intake on hypertension (Continued)
Population Gene SNPs/gene length, bp Chr Position Results Drink Ancestor Reference
MSRA rs4841294 8 10247558 SBP LHD AA,EA
MSRA rs17693945 8 10248500 MAP LHD AA,EA
MSRA rs7832708 8 10332530 SBP LHD EA
MSRA rs11786677 8 10406750 SBP CURD EA
PINX1 rs4551304 8 10807559 DBP,MAP CURD EA,HA
PINX1 rs7814757 8 10817678 SBP CURD EA
RP1L1 rs4841409 8 10658864 SBP CURD EA
RP1L1 rs4841409 8 10658864 MAP CURD,LHD EA
RP1L1 rs10096777 8 10660990 SBP LHD EA
TACC2 rs11200509 10 122256927 PP LHD AA
TARID rs76987554 6 133759717 SBP CURD AA
TNKS rs4383974 8 9761838 SBP CURD AA,EA
TNKS rs35231275 8 9762399 PP CURD EA
TNKS rs9286060 8 9795635 DBP CURD AA,EA
TNKS rs1976671 8 9822124 SBP CURD EA
TNKS rs55868514 8 9822890 DBP CURD EA
UNC5D rs79505281 8 35841899 PP CURD AA
XKR6 rs4841465 8 10962344 SBP CURD,LHD EA
XKR6 rs9969436 8 10985149 MAP LHD AA,EA
HT hypertension, SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure, PP pulse pressure, CURD current drinker (yes/no),
LHD light (1 ± 7 drinks/week) drinking; Ancestry, EA European ancestry, AA African American ancestry, ASA Asian American ancestry, HA Hispanic ancestry
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and meta-analysis of randomized control trials with a
meta-regression of potential effect modifiers revealed
that exercise was associated with a reduction in SBP of
− 4.40 mmHg and in DBP of − 4.17 mmHg at 3–
6 months after the intervention began [57]. Potential
reasons for the association between physical activity and
BP decreases are as follows. First, physical activity helps
maintain appropriate body weight. Second, exercise de-
creases total peripheral resistance [58]. Physical activity
has also been shown to improve insulin sensitivity [59],
which increases high blood pressure via its effect in in-
creasing sodium reabsorption and sympathetic nervous
system activity [60]. An exercise habit can also help
improve one’s other lifestyle habits. Individuals who ex-
ercise every day tend to focus on improving their life-
style in other aspects of their daily lives.
In a cross-sectional study of African American women,
SLC4A5 rs1017783 had a significant interaction with A
allele and AA genotype by physical activity on SBP and
DBP, respectively. In addition, SLC4A5 rs6731545 had a
significant interaction with GA genotype by physical ac-
tivity on both SBP and DBP. A study of Chinese children
showed that interactions between a genetic risk score in-
cluding ATP2B1 rs17249754, fibroblast growth factor 5
(FGF5) rs16998073 polymorphisms, and physical activity
play important roles in the regulation of BP and the
Table 5 Review for interaction of gene and smoking on hypertension
Population Gene SNPs/gene length, bp Chr Position Results Smoking Reference
China ACE I/D EH Smoking 45
China KCNJ11 HT Non-smoking 46
China CYP4A11 rs1126742 1 EH Smoking 47
USA LOC729336 rs11589828 1 230735895 SBP Pack-years 48
LRP1B rs1033284 2 141638258 SBP Pack-years
LRP2 rs2268365 2 169802415 SBP Pack-years
FLJ45964 rs11679072 2 240109156 SBP Pack-years
CNTN4 rs9878978 3 2460969 SBP Pack-years
MECOM rs12634933 3 170512673 SBP Pack-years
PRKG2 rs17484474 4 82345145 SBP Pack-years
GYPA-KRT18P51 rs6537278 4 145477389 SBP Pack-years
RPS6KA2 rs4710117 6 167184091 SBP Pack-years
PPP1R3A-FOXP2 rs12705959 7 113785482 SBP CPD
COLEC10-MAL2 rs6989684 8 120212220 SBP Pack-years
TRAPPC9 rs7823724 8 141473511 SBP Pack-years
ADARB2 rs6560743 10 1627136 SBP Pack-years
OPCML rs7104871 11 132544409 SBP Pack-years
CACNA2D4 rs2286379 12 1772425 SBP Pack-years
SACS-TNFRSF19 rs2297585 13 22942344 SBP Pack-years
FRY rs9533282 13 31525648 SBP Pack-years
GPC5-GPC6 rs9561252 13 92527286 SBP CPD
LOC730007 rs8010717 14 79480194 SBP CPD
NRXN3 rs8010717 14 79480194 SBP Pack-years, smoking
HERC2P6 rs937741 15 21198852 SBP CPD
CYB5B rs12149862 16 68054704 SBP Pack-years
ZSWIM7 rs7211756 17 15840400 SBP Pack-years
CDH19-DSEL rs7234531 18 62721365 SBP Pack-years
MN1 rs133980 22 26352728 SBP CPD, Pack-years
LOC200810 rs7615952 3 127132093 DBP Pack-years
GRB10 rs10275663 7 50765179 DBP CPD
African American NEDD8 rs11158609 14 24688814 SBP Smoking 49
TTYH2 rs8078051 17 72251240 SBP Smoking
HT hypertension, SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure, PP pulse pressure, CPD cigarettes per day
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development of hypertension [61]. ATP2B1 is expressed
in the vascular endothelium and regulates the homeosta-
sis of cellular calcium levels, which is important in con-
trolling the contraction and dilation of vascular smooth
muscles [62]. The most commonly cited effect of FGF-5
is to promote angiogenesis in the heart. FGF-5 acts as
an autocrine/paracrine mechanism of cardiac cell growth
and as a cytoprotective mechanism against irreversible
ischemic damage [63]. FGF-5 rs16998073 polymor-
phisms were significantly associated with hypertension
risk in East Asians [64]. However, no evidence supports
a role for this gene in the pathogenesis of hypertension.
Perspectives
In the era of precision medicine, clinicians who are re-
sponsible for hypertension management should consider
the gene-environment interactions along with the appro-
priate lifestyle components toward the prevention and
treatment of hypertension. The effects and contributions
of other confounding and interaction factors such as
race, age, other lifestyle habits (e.g., lack of sleep [65]
and bathing [66]), and environmental factors (e.g., wea-
ther conditions [67] and air pollution [68]), stress [69],
and social factors [70] must also be determined
comprehensively.
We briefly reviewed the interaction of genetic and en-
vironmental factors along the constituent elements of
hypertension guidelines, but a sufficient amount of evi-
dence has not yet accumulated, and the results of gen-
etic factors often differed in each study. The following
requirements should be considered in future studies: (1)
set of the reproducible environmental factor with simple
and easy way; (2) consider the subjects’ race, gender, and
age; (3) select research subjects so that bias is as small
as possible; (4) use a risk score of the target disease in-
cluding a simple dietary intake and physical activity
questionnaire and examines genetic factors to improve
the risk model; and (5) effectively provide hypertension
management with precision medicine based on the com-
ponents of appropriate lifestyle interventions in hyper-
tension prevention guidelines for a cardiovascular
disease model with the specific gene-environmental fac-
tors being studied.
The Genetic Epidemiology Network of Salt Sensitivity
(The GenSalt) Study obtained novel implications regard-
ing the association between BP responses to dietary so-
dium and potassium and hypertension and identifying
an inverse relation between a BP genetic risk score and
salt and potassium sensitivity of BP [71]. The UK Bio-
bank data recently revealed 107 validated loci for BP, in
a study that showed that BP which is 9–10 mmHg
higher with an over twofold higher risk of hypertension
(in a comparison of the top and bottom quintiles of the
BP genetic risk score distribution) has potential clinical
and public health implications [72]. Although the extent
to which each gene contributes to BP is small, by in-
corporating the concept of a genetic risk score, the con-
tribution of blood pressure has been shown by many
GWAS. BP research will continue to contribute to future
preventive medicine.
Conclusion
We summarize gene-environmental interactions associ-
ated with hypertension by describing common lifestyle
modifications according to the recommendations of
hypertension guidelines in major countries which consist
of the following elements: weight reduction, a healthy
diet, dietary sodium reduction, increasing physical activ-
ity, quitting smoking, and moderate alcohol consump-
tion. We briefly reviewed the interaction of genetic and
environmental factors along the constituent elements of
hypertension guidelines, but a sufficient amount of evi-
dence has not yet accumulated, and the results of gen-
etic factors often differed in each study.
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